


Preclinical-stage, cell and gene therapy biotech

Establishment: Oct. 2020, Tokyo, Japan

Series-A: **\$7.7M**, Grant: **up to \$19M** (Non-dilutive funding) as of Nov. 2024, \$1=150yen

Technology: **Ex vivo expansion of functional Hematopoietic Stem Cell (LT-HSC)**


Celaid's Media



- **High Expansion of LT-HSC, important source for all blood cells (Compared to competitor)**
- **No gene modification**
- **Low cost, high productivity (Use chemical compounds)**

Platform-available for partnering

- Celaid's platform technology can be applied to several cell therapy products
- Several collaborations are proceeding under MTA or co-research agreement



Top-10 global pharma, biotech in the US, Japan

HSC-based product

- HSC Transplantation product
- Ex vivo HSC gene editing product
- Expanded CD34+ for research use

Blood, immune cell product

- Cord blood-derived Red blood cell product
- Cord blood-derived NK-cell product
- iPSC-derived NK-cell product ...etc

12

Problem / Solution for Cell and Gene therapy

Physician




HSC transplantation (bone marrow, cord blood)

Pharma / Biotech



Cell and Gene therapy product development (NK-cell, T-cell etc)

Solution: Selective HSC expansion



Problem

Low count of Stem Cell for transplantation or manufacturing process

Wholly-owned pipeline

- Celaid has 4 pipelines, 1st lead pipeline under development in the US



Allo expanded-HSC product

Pediatric hematological rare disease



Allo expanded-HSC product

Leukemia (blood cancer)



Auto expanded-HSC product

Multiple Myeloma (blood cancer)



Allo expanded-HSC product - off the shelf

Ischemic disease

4

Our Ask

- Find **Investors** for **Series B** fundraise **\$10M (2025/6)**
- Find **collaboration partners** for Pipeline / Platform